Geneva, July 7 -- International Clinical Trials Registry received information related to the study (ISRCTN21343134) titled 'Exploring Symprove product for the management of gastroesophageal reflux disease (GORD) symptoms' on June 29.
Study Type: Interventional
Study Design:
Allocation: Non-randomized controlled trial
Masking: Open (masking not used)
Control: Uncontrolled
Assignment: Single
Purpose: Treatment
Primary Sponsor: Manchester University NHS Foundation Trust
Condition:
Gastroesophageal reflux disease
GORD
Digestive System
Intervention:
This will be a 6-week, single-arm pilot study involving one study visit at the research site and six follow-up calls. We will recruit a minimum of 70 participants with Gastro-oesophageal R...